Resveratrol Brain Drug Enters Phase 2 Trial for Parkinson's Disease
Jupiter Neurosciences launches a 30-patient trial of JOTROL, a high-bioavailability resveratrol formula targeting Parkinson's disease.
Summary
Jupiter Neurosciences has begun enrolling patients in a Phase 2a trial of JOTROL, a specially formulated version of trans-resveratrol designed to reach the brain. Unlike standard resveratrol supplements, JOTROL uses a micellar delivery system that achieved roughly nine times higher blood levels and measurable cerebrospinal fluid concentrations in a Phase 1 study. The 12-week trial will enroll 30 Parkinson's patients across Georgetown University and MedStar Health sites, testing two doses against placebo. Primary goals are safety and pharmacokinetics, with secondary measures including ATP levels and inflammatory biomarkers. Results are expected by mid-2027. Parkinson's affects over one million Americans, and no disease-modifying treatment currently exists, making this early-stage research noteworthy for anyone tracking neurological aging and neuroprotection strategies.
Detailed Summary
Parkinson's disease remains one of the most challenging conditions in neurological aging, with no approved therapy proven to slow its progression. Jupiter Neurosciences is now testing whether a next-generation resveratrol formulation called JOTROL can change that, having launched a Phase 2a trial after promising early safety data.
Resveratrol, a polyphenol found in red grapes and widely used as a longevity supplement, has long shown potential in preclinical studies for neuroprotection and anti-inflammatory effects. The core problem has always been bioavailability — standard resveratrol is poorly absorbed and rarely reaches the brain in meaningful concentrations. JOTROL uses a micellar nanoparticle delivery system to overcome this barrier, achieving approximately nine times higher plasma concentrations than conventional resveratrol and, critically, measurable drug levels in cerebrospinal fluid in Phase 1 healthy volunteers.
The RESET study is a multi-center, randomized, double-blind, placebo-controlled trial enrolling 30 Parkinson's patients at Georgetown University and MedStar Health sites across Washington DC, Maryland, and Virginia. Participants are randomized 1:1:1 to two dose levels or placebo over 12 weeks. Primary endpoints focus on safety, tolerability, and pharmacokinetics. Secondary endpoints include ATP blood levels and inflammatory biomarkers — measures directly relevant to mitochondrial function and neuroinflammation, two central mechanisms in Parkinson's pathology.
For longevity-focused readers, this trial represents a meaningful test of whether a compound already popular in the supplement space can be reformulated into a genuine therapeutic. The CSF penetration data from Phase 1 is the most compelling signal — demonstrating brain exposure is a prerequisite for any CNS drug to work.
Important caveats apply: this is a small, early-stage trial focused primarily on safety rather than efficacy. Results are not expected until mid-2027. JOTROL is not FDA-approved, and supplement-grade resveratrol should not be conflated with this investigational formulation.
Key Findings
- JOTROL achieved ~9x higher plasma bioavailability than standard resveratrol and measurable brain fluid levels in Phase 1.
- Phase 2a trial enrolls 30 Parkinson's patients across 12 weeks at Georgetown University and MedStar Health sites.
- Secondary endpoints include ATP blood levels and inflammatory biomarkers, targeting mitochondrial and neuroinflammatory pathways.
- No serious adverse events were reported across 24 participants in the completed Phase 1 healthy volunteer study.
- Results are projected by first half of 2027; JOTROL remains investigational and is not FDA-approved.
Methodology
This is a news report summarizing a company announcement about trial initiation, sourced from Longevity.Technology, a credible longevity-focused publication. Evidence is based on company-disclosed Phase 1 data and trial registration details; independent peer-reviewed publication of Phase 1 results has not been confirmed in this article.
Study Limitations
This article is based on a company press release and has not been independently verified against peer-reviewed Phase 1 publications. The trial is small at 30 patients and is primarily a safety study, not powered to detect efficacy. Market size and economic burden statistics are cited without primary source attribution and should be verified independently.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.